453 related articles for article (PubMed ID: 11931626)
1. A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening.
McGovern SL; Caselli E; Grigorieff N; Shoichet BK
J Med Chem; 2002 Apr; 45(8):1712-22. PubMed ID: 11931626
[TBL] [Abstract][Full Text] [Related]
2. Identification and prediction of promiscuous aggregating inhibitors among known drugs.
Seidler J; McGovern SL; Doman TN; Shoichet BK
J Med Chem; 2003 Oct; 46(21):4477-86. PubMed ID: 14521410
[TBL] [Abstract][Full Text] [Related]
3. Kinase inhibitors: not just for kinases anymore.
McGovern SL; Shoichet BK
J Med Chem; 2003 Apr; 46(8):1478-83. PubMed ID: 12672248
[TBL] [Abstract][Full Text] [Related]
4. High-throughput assays for promiscuous inhibitors.
Feng BY; Shelat A; Doman TN; Guy RK; Shoichet BK
Nat Chem Biol; 2005 Aug; 1(3):146-8. PubMed ID: 16408018
[TBL] [Abstract][Full Text] [Related]
5. A specific mechanism of nonspecific inhibition.
McGovern SL; Helfand BT; Feng B; Shoichet BK
J Med Chem; 2003 Sep; 46(20):4265-72. PubMed ID: 13678405
[TBL] [Abstract][Full Text] [Related]
6. Be Aware of Aggregators in the Search for Potential Human
Viviani LG; Piccirillo E; Cheffer A; de Rezende L; Ulrich H; Carmona-Ribeiro AM; Amaral AT
Molecules; 2018 Jul; 23(8):. PubMed ID: 30060466
[TBL] [Abstract][Full Text] [Related]
7. Molecular docking and high-throughput screening for novel inhibitors of protein tyrosine phosphatase-1B.
Doman TN; McGovern SL; Witherbee BJ; Kasten TP; Kurumbail R; Stallings WC; Connolly DT; Shoichet BK
J Med Chem; 2002 May; 45(11):2213-21. PubMed ID: 12014959
[TBL] [Abstract][Full Text] [Related]
8. A printable hydrogel microarray for drug screening avoids false positives associated with promiscuous aggregating inhibitors.
Mateen R; Ali MM; Hoare T
Nat Commun; 2018 Feb; 9(1):602. PubMed ID: 29426913
[TBL] [Abstract][Full Text] [Related]
9. Surface plasmon resonance based assay for the detection and characterization of promiscuous inhibitors.
Giannetti AM; Koch BD; Browner MF
J Med Chem; 2008 Feb; 51(3):574-80. PubMed ID: 18181566
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive mechanistic analysis of hits from high-throughput and docking screens against beta-lactamase.
Babaoglu K; Simeonov A; Irwin JJ; Nelson ME; Feng B; Thomas CJ; Cancian L; Costi MP; Maltby DA; Jadhav A; Inglese J; Austin CP; Shoichet BK
J Med Chem; 2008 Apr; 51(8):2502-11. PubMed ID: 18333608
[TBL] [Abstract][Full Text] [Related]
11. Screening in a spirit haunted world.
Shoichet BK
Drug Discov Today; 2006 Jul; 11(13-14):607-15. PubMed ID: 16793529
[TBL] [Abstract][Full Text] [Related]
12. Structure-based virtual screening as a tool for the identification of novel inhibitors against Mycobacterium tuberculosis 3-dehydroquinate dehydratase.
Petersen GO; Saxena S; Renuka J; Soni V; Yogeeswari P; Santos DS; Bizarro CV; Sriram D
J Mol Graph Model; 2015 Jul; 60():124-31. PubMed ID: 26043661
[TBL] [Abstract][Full Text] [Related]
13. Inhibition profiling of human carbonic anhydrase II by high-throughput screening of structurally diverse, biologically active compounds.
Iyer R; Barrese AA; Parakh S; Parker CN; Tripp BC
J Biomol Screen; 2006 Oct; 11(7):782-91. PubMed ID: 16858005
[TBL] [Abstract][Full Text] [Related]
14. Protein promiscuity: drug resistance and native functions--HIV-1 case.
Fernández A; Tawfik DS; Berkhout B; Sanders R; Kloczkowski A; Sen T; Jernigan B
J Biomol Struct Dyn; 2005 Jun; 22(6):615-24. PubMed ID: 15842167
[TBL] [Abstract][Full Text] [Related]
15. Successful virtual screening of a chemical database for farnesyltransferase inhibitor leads.
Perola E; Xu K; Kollmeyer TM; Kaufmann SH; Prendergast FG; Pang YP
J Med Chem; 2000 Feb; 43(3):401-8. PubMed ID: 10669567
[TBL] [Abstract][Full Text] [Related]
16. Stability and equilibria of promiscuous aggregates in high protein milieus.
Coan KE; Shoichet BK
Mol Biosyst; 2007 Mar; 3(3):208-13. PubMed ID: 17308667
[TBL] [Abstract][Full Text] [Related]
17. Stoichiometry and physical chemistry of promiscuous aggregate-based inhibitors.
Coan KE; Shoichet BK
J Am Chem Soc; 2008 Jul; 130(29):9606-12. PubMed ID: 18588298
[TBL] [Abstract][Full Text] [Related]
18. Identification and in vitro evaluation of new leads as selective and competitive glycogen synthase kinase-3β inhibitors through ligand and structure based drug design.
Darshit BS; Balaji B; Rani P; Ramanathan M
J Mol Graph Model; 2014 Sep; 53():31-47. PubMed ID: 25064440
[TBL] [Abstract][Full Text] [Related]
19. Novel inhibitor discovery through virtual screening against multiple protein conformations generated via ligand-directed modeling: a maternal embryonic leucine zipper kinase example.
Mahasenan KV; Li C
J Chem Inf Model; 2012 May; 52(5):1345-55. PubMed ID: 22540736
[TBL] [Abstract][Full Text] [Related]
20. Characterization of aggregates of surface modified fullerenes by asymmetrical flow field-flow fractionation with multi-angle light scattering detection.
Astefanei A; Kok WT; Bäuerlein P; Núñez O; Galceran MT; de Voogt P; Schoenmakers PJ
J Chromatogr A; 2015 Aug; 1408():197-206. PubMed ID: 26169905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
